- Tytuł:
- Rivoceranib, a VEGFR-2 inhibitor, monotherapy in previously treated patients with advanced or metastatic gastric or gastroesophageal junction cancer (ANGEL study): an international, randomized, placebo-controlled, phase 3 trial
- Autorzy:
- Źródło:
-
Gastric Cancer . 27(2):375-386
Czasopismo naukowe